Activity of a novel Hec1-targeted anticancer compound against breast cancer cell lines in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1419-1430

  Huang, Lynn Y L ^a   Chang, Chia Chi ^a   Lee, Ying Shuan ^b   Chang, Jia Ming ^b   Huang, Jiann Jyh ^b   Chuang, Shih Hsien ^b   Kao, Kuo Jang ^a   Lau, Gillian M G ^a   Tsai, Pei Yi ^b   Liu, Chia Wei ^b   Lin, Her Sheng ^b   Lau, Johnson Y N ^a  

^a Taivex Therapeutics Corporation   (Taiwan)

^b DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN DERIVATIVE; PROTEIN HEC1; PROTEIN NEK2; TAI 95; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; N-(4-(4-((5-(2-METHOXYETHOXY)PYRAZINE-2-YL)THIO)-2,6-DIMETHYLPHENYL)THIAZOL-2-YL)ISONICOTINAMIDE; NDC80 PROTEIN, HUMAN; NICOTINAMIDE; NUCLEAR PROTEIN; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; DRUG INDICATION; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MCF-7 CELLS; MICE; MOLECULAR TARGETED THERAPY; NIACINAMIDE; NUCLEAR PROTEINS; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902679614     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0700     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 2012;81:103-22.
3. Skeel RT, Khleif SN. Handbook of cancer chemotherapy. 8th ed. Philadelphia, PA: Wolters Kluwer; 2011.
4. Ouellette M. Biochemical and molecular mechanisms of drug resistance in parasites. Trop Med Int Health 2001;6:874-82. (Pubitemid 33010873)
5. Tungusova OS, Mar'iandyshev AO. Molecular mechanisms of the formation of drug resistance of Mycobacterium tuberculosis (review of the literature). Probl Tuberk 2001;48-9.
6. Kerbel RS. Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer metastasis Rev 2001;20:1-2. (Pubitemid 34074672)
7. Wu X, Zhang J, Zhuang Y, Zhang X, Li G, He X. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis clinical isolates. Chin Med J 1999;112:524-8. (Pubitemid 29283683)
8. Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 2011;11:143.
9. Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, et al. Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res 2008;68:8393-9.
10. Chen Y, Riley DJ, Chen PL, Lee WH. HEC, a novel nuclear protein rich in leucine heptad repeats specifically involved in mitosis. Mol Cell Biol 1997;17:6049-56. (Pubitemid 27411113)
11. Bieche I, Vacher S, Lallemand F, Tozlu-Kara S, Bennani H, Beuzelin M, et al. Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. MolCancer 2011;10:23.
12. Xiao GF, Tang HH. Expression and clinical significance of highly expressed protein in cancer (Hec 1) in human primary gallbladder carcinoma. Xi bao yu fen zi mian yi xue za zhi 2008;24:910-2.
13. Diaz-Rodriguez E, Sotillo R, Schvartzman JM, Benezra R. Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc Natl Acad Sci U S A 2008;105:16719-24.
14. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 1993;7:1407-13. (Pubitemid 23336171)
15. Qiu XL, Li G, Wu G, Zhu J, Zhou L, Chen PL, et al. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. J Med Chem 2009;52:1757-67.
16. Huang LY, Lee YS, Huang JJ, Chang CC, Chang JM, Chuang SH, et al. Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1. J Exp Clin Cancer Res 2014;33:6.
17. Wei R, Ngo B, Wu G, Lee WH. Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosomealignment and signaling of the spindle assembly checkpoint. Mol Biol Cell 2011;22:3584-94.
18. Zheng L, Chen Y, Lee WH. Hec1p, an evolutionarily conserved coiledcoil protein, modulates chromosome segregation through interaction with SMC proteins. Mol Cell Biol 1999;19:5417-28. (Pubitemid 29339900)
19. Martin-Lluesma S, Stucke VM, Nigg EA. Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2. Science 2002;297:2267-70.
20. DeLuca JG, Howell BJ, Canman JC, Hickey JM, Fang G, Salmon ED. Nuf2 and Hec1 are required for retention of the checkpoint proteins Mad1 and Mad2 to kinetochores. Curr Biol 2003;13:2103-9. (Pubitemid 37502528)
21. Tetsuya H, Tokuko H, Yasushi H, Hiroshi K, Tatsuo F. Dynamic behavior of Nuf2-Hec1 complex that localizes to the centrosome and centromere and is essential for mitotic progression in vertebrate cells. J Cell Sci 2003;116:3347-62.
22. DeLuca JG, Gall WE, Ciferri C, Cimini D, Musacchio A, Salmon ED. Kinetochore microtubule dynamics and attachment stability are regulated by Hec1. Cell 2006;127:969-82. (Pubitemid 44792254)
23. DeLuca JG, Dong Y, Hergert P, Strauss J, Hickey JM, Salmon ED, et al. Hec1 and Nuf2 are core components of the kinetochore outer plate essential for organizing microtubule attachment sites. Mol Biol Cell 2005;16:519-31. (Pubitemid 40165552)
24. Janicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 2009;117:219-21.
25. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008;107:309-30. (Pubitemid 351172108)
26. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 2007;30:1545-51.
27. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000;406:775-81.
28. Mo QQ, Chen PB, Jin X, Chen Q, Tang L, Wang BB, et al. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel. Acta Pharmacol Sin 2013;34:541-8.
29. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003;10:43-73. (Pubitemid 36457239)
30. Hill BT, Deuchars K, Hosking LK, Ling V, Whelan RD. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro . J Natl Cancer Inst 1990;82:607-12. (Pubitemid 20115453)
31. Scotto KW, Egan DA. Transcriptional regulation of MDR genes. Cytotechnology 1998;27:257-69. (Pubitemid 29025474)
32. Chen Y, Sharp ZD, Lee WH. HEC binds to the seventh regulatory subunit of the 26 S proteasome and modulates the proteolysis of mitotic cyclins. J Biol Chem 1997;272:24081-7. (Pubitemid 27410994)